Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: JMJD2A participates in cytoskeletal remodeling to regulate castration-resistant prostate cancer docetaxel resistance

Fig. 2

In vivo experiments validating the expression of JMJD2A and cytoskeleton remodeling-related factors in CRPC docetaxel-resistant mice. A Mice PDX model of the control and resistant groups; B Change in the tumor volume of the PDX models after treatment; C Change in the tumor weight of the PDX models after treatment. D PSA levels in mouse serum detected by ELISA; E The pathological changes in tissue samples observed by H&E staining; F miR-34a expression detected by PCR; G The levels of microtubulin α-Tubulin and β-Tubulin, F-actin in tissue samples observed by immunohistochemistry; H JMJD2A, STMN1 and β3-Tubulin protein expression detected by western blot. ***P < 0.001, compared with the control group

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us